Cost-Effectiveness of Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Systematic Review of Cost-Effectiveness Studies for the American College of Physicians

CONCLUSION: Glucagon-like peptide-1 agonists and SGLT2i are of low value as first-line therapy but may be of intermediate value when added to metformin or other background therapy compared with adding nothing. Other drugs and comparisons are of low or uncertain value. Results are sensitive to drug effectiveness and cost assumptions.PRIMARY FUNDING SOURCE: American College of Physicians. (PROSPERO: CRD42022382315).PMID:38639547 | DOI:10.7326/M23-1492

Source: Annals of Internal Medicine - April 19, 2024 Category: Internal Medicine Authors: John T Schousboe Adrienne Landsteiner Tyler Drake Shahnaz Sultan Lisa Langsetmo Anjum Kaka Maylen Anthony Charles J Billington Caleb Kalinowski Kristen Ullman Timothy J Wilt Source Type: research